Residual impurities resulting from the synthetic route, the formulation, or from degradation of the active drug and/or the excipients, may be present in the pharmaceutical products that will be administered to patients. Some of these impurities may present a potential for genotoxicity and therefore pose an additional safety concern to clinical subjects and patients. When genotoxic impurities are detected, these should be controlled and limited, if not avoided, in the final product to ensure the safety of the patients. During drug development, the strategies to control all impurities at safe concentrations are mandatory and regulated by ICH guidelines that are adopted worldwide. However, the effort made to limit impurities must be commensurate with the risk assessed at each phase of clinical development and thereafter for marketing. The webinar provides a general overview of the topic of genotoxic impurities and the approaches to safety evaluations.
Course Objectives:
• Understanding the difference between genotoxicity and mutagenicity
• Recognize the importance of genotoxic impurities evaluations in drug development
• Learn the necessary steps to assess the toxicological profiles of impurities
• Learn the concept of the toxicological threshold for concern (TTC)
• Learn the concept of Permitted Daily Allowance
• Influence and motivate cross-functional colleagues to embrace their critical roles in successful genotoxic impurities evaluation programs
Why Should You Attend:
An effective evaluation of potential genotoxic impurities is essential for the overall success of any drug development program for small molecules. In this webinar expert speaker Stefano Persiani will focus on the basics for an effective genotoxic impurities assessment. A case study will be described to further provide focus on the concepts discussed.
Course Outline:
•Understanding the difference between genotoxicity and mutagenicity
•Recognize the importance of genotoxic impurities evaluations in drug development
•Learn the necessary steps to assess the toxicological profiles of impurities
•Learn the concept of the toxicological threshold for concern (TTC)
•Learn the concept of Permitted Daily Allowance
•Influence and motivate colleagues to participate in genotoxic impurities evaluation programs
• Case study
What You Get:
• Training Materials
• Live Q&A Session with our Expert
• Participation Certificate
• Access to Signup Community (Optional)
• Reward Points
Who Will Benefit:
• Project managers
• Licensing managers
• Quality control and assurance managers
• Corporate quality managers
• Toxicology specialists
• Drug supply and manufacturing operations
• Medicinal chemists
• Senior management
• Quality assurance and plant management personnel
• Pharmaceutical development managers
• Formulation specialists
• Regulatory specialists
• Clinical Research Associates
• Clinical study monitors
• Consultants
• Quality system auditors
Bioavailability and Bioequivalence Studies submitted in NDAs and INDs
Get Instant Access 90 Minutes View Program |
Veterinary Feed Directive (VFD) Final Rule – What you need to know?
Get Instant Access 60 Minutes View Program |
Packaging and Labeling for Commercial and Clinical Products
Get Instant Access 90 Minutes View Program |
Providing DMFs in eCTD format
Get Instant Access 90 Minutes View Program |
QSR-Compliant Equipment Control & Validation of Processes in the Manufacturing Environment
Get Instant Access 90 Minutes View Program |
Get Instant Access On-Demand Access
Preparing for the ICE Storm: What to Do During I 9 Audits and ICE Raids
Janette S. Levey
Human Resources
Get Instant Access On-Demand Access
OSHA Inspections and Investigations-How to Manage Them
Irwin Dobrushin
Environment Health and Safety | OSHA
Get Instant Access On-Demand Access
29 CFR 1904: OSHA's New Injury Recordkeeping E-Submission Rule
Occupational Safety and Health Administration
Get Instant Access On-Demand Access
Working with Excel Databases: Sort, Filter, Subtotal and More
Cathy Horwitz
Cross Industry | Skill Enhancement
Get Instant Access On-Demand Access
Writing Audit Reports
Jonnie T. Keith CIA, CFE, CGAP, CICA
Governance, Risk and Compliance
Get Instant Access On-Demand Access
BSA Reporting Requirements
Banking and Financial Services Industry
Get Instant Access On-Demand Access
Human Factors-Usability Based on ISO 62366
Medical Device | Diagnostic | Pharmaceutical | Biologics fields
Get Instant Access On-Demand Access
Chat GPT for Project Managers
Charles H. Paul
All FDA Regulated Industry